Key facts
- It has raised $420K; the latest was Later Stage VC in Mar 2025.
- Notable investors include US National Science Foundation, SOSV, HAX, Innovation Works, AlphaLab Health.
- InnSight Technology has filed 1 Form D with the SEC, most recently Dec 2022 ($120K sold to 2 investors).
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for InnSight Technology
- ·The full record, as it builds
Funding rounds
No funding rounds for InnSight Technology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About InnSight Technology
Developer of novel ophthalmic devices designed to advance diagnostics and evaluation of eye disease. The company's ophthalmic biosensor is a novel, hand-held, point-of-service device for the detection of anterior ophthalmic injuries, and also develops novel nanotechnology-based medical devices to address needs in clinical ophthalmology, enabling clinicians to improve ocular care.
- Sector
- Healthcare
- HQ
- Pittsburgh, PA, United States
- Founded
- 2014
- Employees
- 3
- Website
- innsightech.com/
- Ownership
- Privately Held (backing)
InnSight Technology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in InnSight Technology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on InnSight Technology in its N-PORT filings yet. We sweep new filings monthly.